- Home
- TTAM vs EWTX Comparison
TTAM vs EWTX Comparison
Compare TTAM & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TTAM
- EWTX
- Stock Information
- Founded
- TTAM 1902
- EWTX 2017
- Country
- TTAM Belgium
- EWTX United States
- Employees
- TTAM N/A
- EWTX N/A
- Industry
- TTAM
- EWTX Biotechnology: Pharmaceutical Preparations
- Sector
- TTAM
- EWTX Health Care
- Exchange
- TTAM NYSE
- EWTX Nasdaq
- Market Cap
- TTAM 2.3B
- EWTX 2.3B
- IPO Year
- TTAM 2025
- EWTX 2021
- Fundamental
- Price
- TTAM $13.28
- EWTX $20.13
- Analyst Decision
- TTAM Strong Buy
- EWTX Buy
- Analyst Count
- TTAM 5
- EWTX 8
- Target Price
- TTAM $17.20
- EWTX $45.38
- AVG Volume (30 Days)
- TTAM 429.9K
- EWTX 1.5M
- Earning Date
- TTAM 03-26-2025
- EWTX 03-03-2025
- Dividend Yield
- TTAM N/A
- EWTX N/A
- EPS Growth
- TTAM 180.40
- EWTX N/A
- EPS
- TTAM 0.95
- EWTX N/A
- Revenue
- TTAM $1,634,393,000.00
- EWTX N/A
- Revenue This Year
- TTAM N/A
- EWTX N/A
- Revenue Next Year
- TTAM N/A
- EWTX N/A
- P/E Ratio
- TTAM $14.02
- EWTX N/A
- Revenue Growth
- TTAM 41.82
- EWTX N/A
- 52 Week Low
- TTAM $12.61
- EWTX $14.90
- 52 Week High
- TTAM $17.78
- EWTX $38.12
- Technical
- Relative Strength Index (RSI)
- TTAM N/A
- EWTX 28.86
- Support Level
- TTAM N/A
- EWTX $21.58
- Resistance Level
- TTAM N/A
- EWTX $25.36
- Average True Range (ATR)
- TTAM 0.00
- EWTX 1.99
- MACD
- TTAM 0.00
- EWTX -0.38
- Stochastic Oscillator
- TTAM 0.00
- EWTX 2.67
About TTAM TITAN AMERICA SA
Titan America SA is a vertically integrated, multi-regional manufacturer and supplier of heavy building materials and services operating primarily on the Eastern Seaboard. The Company, through its wholly owned subsidiaries, primarily operates in the manufacture, distribution, and sale of cement, fly ash, aggregates, ready-mix concrete, and concrete blocks to resellers and construction contractors in the Eastern region of the United States.
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.